
HURA Stock Forecast & Price Target
HURA Analyst Ratings
Bulls say
TuHURA Biosciences Inc is positioned to benefit from several upcoming value inflection points, including preliminary results from the Phase 1b/2a trial of its personalized cancer vaccine, IFx-2.0, which could significantly broaden its addressable patient population. The company has also indicated potential upside from its anti-VISTA mAb candidate (TBS-2025) in combination with a menin inhibitor, with interim results expected to be released in late 2026. Additionally, the recent decline in share price against the backdrop of an overall positive sector performance presents what is viewed as an attractive entry point for investors, reinforcing the company's growth prospects in immuno-oncology.
Bears say
TuHURA Biosciences Inc. is facing significant challenges that contribute to a negative outlook for its stock, primarily due to potential negative clinical results with its personalized cancer vaccine candidate, IFx-2.0, and delays in advancing its pipeline candidates into registrational programs. The company's inability to secure timely regulatory approvals and the competitive landscape surrounding checkpoint inhibitors further exacerbate these concerns, along with the medium-to-long term risk of shareholder dilution. Additionally, the company's shares have experienced a sharp decline of approximately 62% over the past month, contrasting starkly with the broader market index, raising further alarm among investors.
This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
HURA Analyst Forecast & Price Prediction
Start investing in HURA
Order type
Buy in
Order amount
Est. shares
0 shares